<?xml version="1.0" encoding="UTF-8"?>
<p>The drug sodium salicylate (NaSal) (sodium 2-hydroxybenzoate) is classified by the WHO in the ATC system N02BA04, which is other analgesics and antipyretics, salicylic acid and derivatives, a group of compounds first discovered in willow trees. The extract obtained from this tree has been used as a natural anti-inflammatory medicine for centuries. NaSal belongs to a large group of compounds known as nonsteroidal anti-inflammatory drugs (NSAIDs), exerting its mechanism of action by decreasing prostaglandin E2 by inhibiting cyclooxygenase enzyme (COX) and inhibiting NF-ÎºB activation [
 <xref rid="B168-biomolecules-11-00011" ref-type="bibr">168</xref>,
 <xref rid="B169-biomolecules-11-00011" ref-type="bibr">169</xref>]. This immunomodulatory effect is related to the antiviral effect of sodium salicylate against RSV infection in A549 cells [
 <xref rid="B170-biomolecules-11-00011" ref-type="bibr">170</xref>], CMV in human coronary artery smooth muscle cells (SMCs) (2.0 mmol/L) [
 <xref rid="B171-biomolecules-11-00011" ref-type="bibr">171</xref>], and the flavivirus JEV in neuronal and nonneuronal cells (N18 and BHK21 cells; 5 mM) [
 <xref rid="B172-biomolecules-11-00011" ref-type="bibr">172</xref>].
</p>
